NasdaqGS - Nasdaq Real Time Price USD

Pharvaris N.V. (PHVS)

15.99

-0.40

(-2.44%)

At close: May 23 at 4:00:00 PM EDT

15.99

0.00

(0.00%)

After hours: May 23 at 4:00:11 PM EDT

Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses

ZUG, Switzerland, May 19, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at three upcoming congresses: the 14th C1-Inhibitor Deficiency and Angioedema Works

GlobeNewswire 4 days ago

PHVS
-2.44%
Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update

Enrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expected in 2H2026Attack dataset continues to accumulate in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidence in clinical timelinesTQT study waivers received from FDA for both deucrictibant extended-release formulation and deucrictibant immediate-release formulationPharvaris Management to host R&D call on Jun

GlobeNewswire 10 days ago

PHVS
-2.44%
Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4

Expansion of potential treatment applications of deucrictibant in people living with bradykinin-mediated angioedemaZUG, Switzerland, May 12, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE), including HAE with normal C1 inhibitor and acquired angioedema due to C1 inhibitor deficiency (A

GlobeNewswire 11 days ago

PHVS
-2.44%
Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Target enrollment achieved in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidence in clinical timelinesEnrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expected in 2H2026Orphan medicinal product designation granted to deucrictibant in Europe for the treatment of bradykinin-mediated angioedemaData presented at recent congresses reinforces the value of deucrict

GlobeNewswire last month

PHVS
-2.44%
Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission

ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that the European Commission (EC) has granted orphan designation to its investigational drug, deucrictibant, for the treatment

GlobeNewswire last month

PHVS
-2.44%
Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress

Reduced monthly HAE attack rate maintained for at least 1.5 years in CHAPTER-1 OLE study; median proportion of days with symptoms in OLE was further reduced to zero daysAll participants in CHAPTER-1 OLE who had reached week 62 reported improved health-related quality of lifeOngoing RAPIDe-2 extension study includes efficacy data from seven upper airway, including laryngeal, attacks; median time to onset of symptom relief was 0.9 hours (N=7)In both extension studies, deucrictibant was generally w

GlobeNewswire 2 months ago

PHVS
-2.44%
Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025

ZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that its management will participate in the Leerink Partners Global Healthcare Conference 2025, taking place from March 10-12,

GlobeNewswire 2 months ago

PHVS
-2.44%
We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Simply Wall St. 2 months ago

PHVS
-2.44%
Why Pharvaris (PHVS) Is Advancing Today

Pharvaris (PHVS) is climbing 3% after investment bank JMP Securities raised its price target on the shares to $55, based on its optimism about the company’s prophylactic treatment for Hereditary Angioedema (HAE). Why JMP Securities Increased Its Price Target After evaluating other companies’ treatments for the rare disease of HAE, which causes extensive swelling, JMP […]

Insider Monkey 3 months ago

PHVS
-2.44%
Why Is Andreas Halvorsen Bullish On Pharvaris N.V. (PHVS) Now?

We recently compiled a list of the Billionaire Andreas Halvorsen’s Top 15 Long-Term Stock Picks. In this article, we are going to take a look at where Pharvaris N.V. (NASDAQ:PHVS) stands against Andreas Halvorsen’s other long-term stock picks. Andreas Halvorsen is a prominent Norwegian hedge fund manager and the co-founder of Viking Global, one of the […]

Insider Monkey 3 months ago

PHVS
-2.44%
Pharvaris Outlines 2025 Strategic Priorities

Initiated CHAPTER-3, the pivotal Phase 3 study of deucrictibant for prophylaxis against hereditary angioedema (HAE) attacks in 2024; topline data anticipated in 2H2026Enrollment in RAPIDe-3, the pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, continuing as planned; topline data anticipated in 1Q2026Study initiation of deucrictibant for the treatment of acquired angioedema due to C1-INH deficiency (AAE-C1INH) anticipated in 2025Operating from a strong financial

GlobeNewswire 4 months ago

PHVS
-2.44%
Pharvaris price target lowered to $46 from $50 at JMP Securities

JMP Securities analyst Jonathan Wolleben lowered the firm’s price target on Pharvaris (PHVS) to $46 from $50 and keeps an Outperform rating on the shares as part of a broader note on Biotechnology. The firm highlighted key upcoming catalysts for its coverage universe over the next 12 months, ahead of what is shaping up to be a “busy” 2025, and noted that it still has several events expected between now and the end of the year which could provide a reason for “cheer” this holiday season. Publishe

TipRanks 5 months ago

PHVS
-2.44%
Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Positive long-term extension data highlighting the differentiated profile of deucrictibant for the prevention and treatment of HAE attacks presented at recent medical congressesIntend to engage in clinical development of deucrictibant for the treatment of acquired angioedema due to C1-INH deficiency (AAE-C1INH)Initiation of CHAPTER-3 global pivotal Phase 3 clinical study of deucrictibant for the prophylactic treatment of HAE using once-daily extended-release tablet expected by YE2024Operating fr

GlobeNewswire 6 months ago

PHVS
-2.44%
Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference

ZUG, Switzerland, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced that its management will participate in the Inaugural Guggenheim Securities Healthcare Innovation Conference, taking place from November 11-13, 2024, at the InterContinental Boston. Details are as follows: Format: Fireside ChatDate, time: Wednesday, N

GlobeNewswire 6 months ago

PHVS
-2.44%
Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting

Data from randomized clinical studies and long-term extension studies support deucrictibant’s potential best-in-class profile, detailing its injectable-like efficacy, placebo-like tolerability, and oral convenienceZUG, Switzerland, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced data from seven posters that will be

GlobeNewswire 6 months ago

PHVS
-2.44%
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings

ZUG, Switzerland, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of multiple abstracts at several upcoming scientific meetings. Presentation details are as follows: American College of Allergy, Asthma, & Immunology’s Annual Scientific Meeting (ACAAI), Boston, October 24-28, 2024. Seven abstracts have

GlobeNewswire 7 months ago

PHVS
-2.44%
Pharvaris to Host Virtual Investor Event on October 23, 2024

ZUG, Switzerland, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced it will host a virtual investor event to discuss the unmet need in both the prophylactic and on-demand treatment of HAE attacks, the potential of deucrictibant to address to needs, and the current HAE market dynamics, on Wednesday, October 23, 2024, a

GlobeNewswire 7 months ago

PHVS
-2.44%
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop

ZUG, Switzerland, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of six abstracts, two for oral presentation and four for poster presentation, at the 2024 Global Angioedema Forum – HAEi Global Leadership Workshop, taking place in Copenhagen, Denmark, from Oct. 4-5, 2024. Details are as follows: Title

GlobeNewswire 7 months ago

PHVS
-2.44%
Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Simply Wall St. 7 months ago

PHVS
-2.44%
Pharvaris Provides Business Update and Expands Development Program for Deucrictibant

CHAPTER-3, the global pivotal Phase 3 clinical study of deucrictibant for the prophylactic treatment for HAE using once-daily extended-release tablet, is expected to initiate by YE2024Differentiated deucrictibant profile, including long-term extension results, to be highlighted in clinical, real-world, nonclinical, and discovery data presentations at the 2024 Bradykinin SymposiumPharvaris intends to pursue clinical development in acquired angioedema as a newly named indicationPharvaris to host a

GlobeNewswire 8 months ago

PHVS
-2.44%

Performance Overview

Return	PHVS	S&P 500 (^GSPC)
YTD	-16.59%	-1.34%
1-Year	-18.21%	+10.16%
3-Year	-5.94%	+46.03%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Pharvaris N.V. (PHVS)

Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses

Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update

Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4

Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission

Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress

Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Why Pharvaris (PHVS) Is Advancing Today

Why Is Andreas Halvorsen Bullish On Pharvaris N.V. (PHVS) Now?

Pharvaris Outlines 2025 Strategic Priorities

Pharvaris price target lowered to $46 from $50 at JMP Securities

Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference

Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings

Pharvaris to Host Virtual Investor Event on October 23, 2024

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

Pharvaris Provides Business Update and Expands Development Program for Deucrictibant

Performance Overview